Different elemental infant formulas show equivalent phosphorus and calcium bioavailability in healthy volunteers
Clemens Bergwitz1, Simone R B M Eussen2, Pilou L H R Janssens2
1Yale University School of Medicine, Section of Endocrinology and Metabolism, New Haven, CT, USA.
Insights
This study found that two elemental infant formulas, Neocate and Elecare, demonstrate equivalent phosphorus and calcium bioavailability in healthy adults, even when taking acid-suppressive medication. This confirms their suitability for individuals requiring specialized nutrition.
Area of Science:
- Clinical Nutrition
- Human Metabolism
- Pharmacokinetics
Background:
- Hypophosphatemia is a risk with elemental formulas in children with complex conditions.
- Elemental formulas are used for specialized nutritional support.
- Gastric acid-suppressive medication can affect nutrient absorption.
Purpose of the Study:
- To evaluate and compare the bioavailability of phosphorus from two commercial elemental formulas (Neocate and Elecare).
- To assess the bioequivalence of these two products in healthy volunteers.
- To determine if gastric acid-suppressive medication impacts phosphorus bioavailability from these formulas.
Main Methods:
- A single-center, double-blind, randomized, cross-over study in healthy volunteers with esomeprazole-induced hypochlorhydria.
- Subjects received a standardized low phosphorus meal followed by fasting, then consumed one of the two elemental formulas (1g phosphorus, 1217 kcal).
- Blood and urine samples were collected over 6 hours to measure serum and urinary phosphate and calcium levels, assessing Area Under the Curve (AUC) and peak concentrations (Cpeak).
Main Results:
- Serum phosphate bioavailability met bioequivalence criteria for both formulas (AUC0-360 GMR: 1.041, Cpeak GMR: 1.020).
- Serum calcium bioavailability also demonstrated bioequivalence (AUC0-360 GMR: 1.002, Cpeak GMR: 0.991).
- Urinary creatinine-corrected phosphate did not meet bioequivalence criteria, though calcium excretion did.
Conclusions:
- Both Neocate and Elecare exhibit equivalent serum phosphorus and calcium bioavailability in healthy adults.
- The findings support the use of these elemental formulas even in individuals taking acid-suppressive medication.
- This study provides crucial data on the nutritional equivalence of these specialized infant formulas.
Abstract:
Retrospective chart reviews have reported hypophosphatemia associated with elemental formula use in infants and children with systemic disease involving multiple diagnoses. The present study aims to evaluate the bioavailability of phosphorus from 2 commercial elemental formulas and to test our hypothesis of bioequivalence of the 2 products in healthy volunteers receiving gastric acid-suppressive medication. A single-center, double-blind, randomized, cross-over study was conducted in healthy volunteers with esomeprazole-induced hypochlorhydria. After a standardized low phosphorus meal followed by overnight fasting, subjects consumed 1 gram of phosphorus in a single oral dose of 1217 kcal of Product A (Neocate) or Product B (Elecare). The alternate product was given following a 1-week washout period. Blood and urine were collected at baseline and different time-points for up to 6 hours after product consumption. Area-under-the-curve (AUC) and peak values (Cpeak) for serum phosphate and calcium and urinary creatinine-corrected phosphate and calcium were assessed for bioequivalence of Products A and B. Results show that the geometric mean ratio (GMR) and 90% CI for serum phosphate were 1.041 (0.998-1.086) and 1.020 (0.963-1.080) for AUC0-360 and Cpeak, respectively, meeting the predetermined criteria for bioequivalence. Urinary creatinine-corrected phosphate followed a similar pattern after intake of Product A and B, but did not reach bioequivalence criteria (GMR: AUC70-370 = 1.105 (0.918-1.330); Cpeak = 1.182 (1.040-1.343)). Serum calcium concentrations (GMR: AUC0-360 = 1.002 (0.996-1.009); Cpeak = 0.991 (0.983-0.999)) and urinary creatinine-corrected calcium excretion (GMR: AUC70-370 = 1.117 (1.023-1.219); Cpeak = 1.157 (1.073-1.247)) demonstrated bioequivalence of the products. In conclusion, both elemental infant formulas showed equivalent serum phosphorus and calcium bioavailability in healthy volunteers even if combined with treatment with acid-suppressive medication.
Related Concept Videos
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Bioequivalence: Overview
Bioavailability Study Design: Healthy Subjects Versus Patients
Bioavailability Study Design: Absolute Versus Relative Bioavailability
Pharmaceutical Equivalents
Introduction to Electrolytes
Role of Sodium
One...


